DRMA is expected to report earnings to rise 13.65% to -54 cents per share on August 18
Q2'26
Est.
$-0.55
Q1'26
Beat
by $1.02
Q4'25
Missed
by $1.02
Q3'25
Missed
by $1.33
Q2'25
Missed
by $1.22
The last earnings report on May 13 showed earnings per share of -47 cents, beating the estimate of -150 cents. With 58.87K shares outstanding, the current market capitalization sits at 4.99M.
A.I.dvisor indicates that over the last year, DRMA has been loosely correlated with PVLA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if DRMA jumps, then PVLA could also see price increases.
DRMA sees its Stochastic Oscillator climbs out of oversold territory
On June 17, 2026, the Stochastic Oscillator for DRMA moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on DRMA as a result. In of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for DRMA just turned positive on June 22, 2026. Looking at past instances where DRMA's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DRMA advanced for three days, in of 194 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
DRMA moved below its 50-day moving average on June 18, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DRMA crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
DRMA broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DRMA entered a downward trend on June 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.771) is normal, around the industry mean (20.966). P/E Ratio (0.090) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). DRMA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DRMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
